X-132628935-T-C
Position:
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 1P and 4B. PP3BS2
The NM_001394073.1(HS6ST2):āc.1226A>Gā(p.Asp409Gly) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000198 in 1,209,505 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 8 hemizygotes in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.00011 ( 0 hom., 4 hem., cov: 23)
Exomes š: 0.000011 ( 0 hom. 4 hem. )
Consequence
HS6ST2
NM_001394073.1 missense
NM_001394073.1 missense
Scores
9
4
4
Clinical Significance
Conservation
PhyloP100: 8.02
Genes affected
HS6ST2 (HGNC:19133): (heparan sulfate 6-O-sulfotransferase 2) Heparan sulfate proteoglycans are ubiquitous components of the cell surface, extracellular matrix, and basement membranes, and interact with various ligands to influence cell growth, differentiation, adhesion, and migration. This gene encodes a member of the heparan sulfate (HS) sulfotransferase gene family, which catalyze the transfer of sulfate to HS. Different family members and isoforms are thought to synthesize heparan sulfates with tissue-specific structures and functions. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -3 ACMG points.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.776
BS2
High Hemizygotes in GnomAd4 at 4 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HS6ST2 | NM_001394073.1 | c.1226A>G | p.Asp409Gly | missense_variant | 5/5 | ENST00000370833.7 | NP_001381002.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HS6ST2 | ENST00000370833.7 | c.1226A>G | p.Asp409Gly | missense_variant | 5/5 | 5 | NM_001394073.1 | ENSP00000359870.3 |
Frequencies
GnomAD3 genomes AF: 0.000107 AC: 12AN: 111672Hom.: 0 Cov.: 23 AF XY: 0.000118 AC XY: 4AN XY: 33826
GnomAD3 genomes
AF:
AC:
12
AN:
111672
Hom.:
Cov.:
23
AF XY:
AC XY:
4
AN XY:
33826
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000333 AC: 6AN: 180387Hom.: 0 AF XY: 0.0000450 AC XY: 3AN XY: 66683
GnomAD3 exomes
AF:
AC:
6
AN:
180387
Hom.:
AF XY:
AC XY:
3
AN XY:
66683
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000109 AC: 12AN: 1097833Hom.: 0 Cov.: 31 AF XY: 0.0000110 AC XY: 4AN XY: 363343
GnomAD4 exome
AF:
AC:
12
AN:
1097833
Hom.:
Cov.:
31
AF XY:
AC XY:
4
AN XY:
363343
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000107 AC: 12AN: 111672Hom.: 0 Cov.: 23 AF XY: 0.000118 AC XY: 4AN XY: 33826
GnomAD4 genome
AF:
AC:
12
AN:
111672
Hom.:
Cov.:
23
AF XY:
AC XY:
4
AN XY:
33826
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
2
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 15, 2023 | The c.1226A>G (p.D409G) alteration is located in exon 6 (coding exon 5) of the HS6ST2 gene. This alteration results from a A to G substitution at nucleotide position 1226, causing the aspartic acid (D) at amino acid position 409 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
D;.;.;D;.
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
.;.;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D
MetaSVM
Uncertain
T
MutationAssessor
Benign
L;.;.;L;.
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D;.;.;.
REVEL
Pathogenic
Sift
Benign
T;T;.;.;.
Sift4G
Benign
T;T;T;T;.
Polyphen
D;.;.;D;.
Vest4
MutPred
Gain of relative solvent accessibility (P = 0.09);.;.;Gain of relative solvent accessibility (P = 0.09);.;
MVP
MPC
1.8
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at